S. Browne, M. Roe, and A. Lane, Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia, Acta Psychiatr Scand, vol.94, issue.2, pp.118-124, 1996.

W. C. Chang, R. Cheung, and C. Hui, Rate and risk factors of depressive symptoms in Chinese patients presenting with first-episode non-affective psychosis in Hong Kong, Schizophr Res, vol.168, issue.1-2, pp.99-105, 2015.

R. P. Munhoz, B. Filho, D. Teive, and H. , Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype, Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol, 2016.

A. Hasan, P. Falkai, and T. Wobrock, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the longterm treatment of schizophrenia and management of antipsychotic-induced side effects, World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry, vol.14, issue.1, pp.2-44, 2013.

J. M. Kane, Pharmacologic treatment of schizophrenia, Biol Psychiatry, vol.46, issue.10, pp.1396-1408, 1999.

D. Novick, J. M. Haro, J. Bertsch, and P. M. Haddad, Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study, J Clin Psychopharmacol, vol.30, issue.5, pp.531-540, 2010.

S. Pappa and P. Dazzan, Spontaneous movement disorders in antipsychotic-naive patients with firstepisode psychoses: a systematic review, Psychol Med, vol.39, issue.7, pp.1065-1076, 2009.

J. H. Bower, D. M. Maraganore, S. K. Mcdonnell, and W. A. Rocca, Incidence and distribution of parkinsonism in Olmsted County, Neurology, vol.52, issue.6, pp.1214-1220, 1976.

M. Tinazzi, F. Morgante, and A. Matinella, Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study, Schizophr Res, vol.152, issue.2-3, pp.344-349, 2014.

M. Tinazzi, A. Cipriani, and A. Matinella, FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism, Schizophr Res, vol.123, issue.1, pp.40-45, 2012.

J. K. Rybakowski, K. Vansteelandt, and A. Remlinger-molenda, Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.24, issue.9, pp.1500-1505, 2014.

Z. Othman, M. Ghazali, A. Razak, and M. Husain, Severity of Tardive Dyskinesia and Negative Symptoms are Associated with Poor Quality of Life in Schizophrenia Patients (PDF Download Available), Int Med J, vol.20, pp.677-680, 2013.

P. P. Lerner, C. Miodownik, and V. Lerner, Tardive dyskinesia (syndrome): Current concept and modern approaches to its management, Psychiatry Clin Neurosci, vol.69, issue.6, pp.321-334, 2015.

D. G. Owens, E. C. Johnstone, and C. D. Frith, Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics, Arch Gen Psychiatry, vol.39, issue.4, pp.452-461, 1982.

D. D. Miller, J. P. Mcevoy, and S. M. Davis, Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial, Schizophr Res, vol.80, issue.1, pp.33-43, 2005.

S. Leucht, C. Corves, D. Arbter, R. R. Engel, C. Li et al., Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: a meta-analysis, Lancet Lond Engl, vol.373, issue.9657, p.61764, 2009.

C. Rummel-kluge, K. Komossa, and S. Schwarz, Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons, Schizophr Bull, vol.38, issue.1, pp.167-177, 2012.

K. Yoshida, R. R. Bies, and T. Suzuki, Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data, Schizophr Res, vol.153, issue.1-3, pp.184-188, 2014.

F. Berna, D. Misdrahi, and L. Boyer, Akathisia: prevalence and risk factors in a communitydwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset, Schizophr Res, vol.169, issue.1-3, pp.255-261, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01896595

M. Carbon, C. Hsieh, J. M. Kane, and C. U. Correll, Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis, J Clin Psychiatry, 2017.

F. Schürhoff, G. Fond, and F. Berna, A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap, Eur Psychiatry J Assoc Eur Psychiatr, vol.30, issue.6, pp.728-735, 2015.

S. R. Kay, A. Fiszbein, and L. A. Opler, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, vol.13, issue.2, pp.261-276, 1987.

R. S. Wallwork, R. Fortgang, R. Hashimoto, D. R. Weinberger, and D. Dickinson, Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia, Schizophr Res, vol.137, issue.1, pp.246-250, 2012.

C. Lançon, P. Auquier, R. G. Bernard, D. Toumi, and M. , Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS), J Affect Disord, vol.58, issue.2, pp.107-115, 2000.

M. J. Byerly, P. A. Nakonezny, and A. J. Rush, The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder, Schizophr Res, vol.100, issue.1-3, pp.60-69, 2008.

D. Misdrahi, A. Tessier, and J. Swendsen, Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence: Results From the FACE-SZ Dataset, J Clin Psychiatry, vol.77, issue.9, pp.1130-1136, 2016.

S. Leucht, M. Samara, S. Heres, M. X. Patel, S. W. Woods et al., Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method, Schizophr Bull, vol.40, issue.2, pp.314-326, 2014.

W. Knol, C. Keijsers, P. Jansen, and R. J. Van-marum, Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research, J Clin Psychopharmacol, vol.30, issue.1, pp.57-63, 2010.

S. Janno, M. M. Holi, K. Tuisku, and K. Wahlbeck, Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population, BMC Neurol, vol.5, issue.1, p.5, 2005.

N. Bark, D. Florida, N. Gera, R. Varardi, L. Harghel et al., Evaluation of the routine clinical use of the Brief Psychiatric Rating Scale (BPRS) and the Abnormal Involuntary Movement Scale (AIMS). -Semantic Scholar, J Psychiatr Pract, vol.17, pp.300-303, 2011.

P. Czobor, R. A. Van-dorn, L. Citrome, R. S. Kahn, W. W. Fleischhacker et al., Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.25, issue.8, pp.1158-1166, 2015.

T. E. Hansen, D. E. Casey, and W. F. Hoffman, Neuroleptic intolerance, Schizophr Bull, vol.23, issue.4, pp.567-582, 1997.

S. Janno, M. Holi, K. Tuisku, and K. Wahlbeck, Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients, Am J Psychiatry, vol.161, issue.1, pp.160-163, 2004.

M. Parksepp, Ü. Ljubajev, K. Täht, and S. Janno, Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients, Nord J Psychiatry, vol.70, issue.7, pp.498-502, 2016.

C. U. Correll, C. Rummel-kluge, C. Corves, J. M. Kane, and S. Leucht, Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials, Schizophr Bull, vol.35, issue.2, pp.443-457, 2009.

M. J. Minzenberg, J. H. Poole, C. Benton, and S. Vinogradov, Association of anticholinergic load with impairment of complex attention and memory in schizophrenia, Am J Psychiatry, vol.161, issue.1, pp.116-124, 2004.

T. Q. Mentzel, R. Lieverse, O. Bloemen, W. Viechtbauer, and P. N. Van-harten, Genetic Risk and Outcome of Psychosis (GROUP) Investigators. High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders, J Clin Psychopharmacol, vol.37, issue.2, pp.231-238, 2017.

V. Peralta and M. J. Cuesta, Negative parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited, Schizophr Res, vol.40, issue.3, pp.245-253, 1999.

L. Docx, M. Morrens, and C. Bervoets, Parsing the components of the psychomotor syndrome in schizophrenia, Acta Psychiatr Scand, vol.126, issue.4, pp.256-265, 2012.

A. Heinz, M. B. Knable, and R. Coppola, Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients, Schizophr Res, vol.31, issue.1, pp.19-26, 1998.

H. Rollema, M. Skolnik, D. 'engelbronner, J. Igarashi, K. Usuki et al., MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies, J Pharmacol Exp Ther, vol.268, issue.1, pp.380-387, 1994.

D. V. Jeste, J. P. Lacro, B. Palmer, R. E. Harris, M. J. Caligiuri et al., Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients, Am J Psychiatry, vol.156, issue.2, pp.309-311, 1999.

D. Tarsy and R. J. Baldessarini, Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?, Mov Disord, vol.21, issue.5, pp.589-598, 2006.

J. T. Wegner, F. Catalano, J. Gibralter, and J. M. Kane, Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology, Arch Gen Psychiatry, vol.42, issue.9, pp.860-865, 1985.

J. L. Waddington and H. A. Youssef, An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms, Am J Psychiatry, vol.143, issue.9, pp.1162-1165, 1986.

J. L. Waddington, H. A. Youssef, C. Dolphin, and A. Kinsella, Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality, Arch Gen Psychiatry, vol.44, issue.10, pp.907-912, 1987.

W. Byne, L. White, M. Parella, R. Adams, P. D. Harvey et al., Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment, Int J Geriatr Psychiatry, vol.13, issue.7, pp.473-479, 1998.

J. Q. Wu, D. C. Chen, and Y. L. Tan, Cognition impairment in schizophrenia patients with tardive dyskinesia: association with plasma superoxide dismutase activity, Schizophr Res, vol.152, issue.1, pp.210-216, 2014.

J. Q. Wu, D. C. Chen, and Y. L. Tan, Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia, Psychopharmacology (Berl), vol.232, issue.1, pp.223-232, 2015.

P. Seeman, Schizophrenia and dopamine receptors, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.23, issue.9, pp.999-1009, 2013.

J. T. Hinkle, K. Perepezko, and L. S. Rosenthal, Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias, Parkinsonism Relat Disord, 2017.